Last reviewed · How we verify
Fludarabine, Busulfan, and ATG
Fludarabine, Busulfan, and ATG is a Small molecule drug developed by University of Chicago. It is currently in Phase 1 development.
At a glance
| Generic name | Fludarabine, Busulfan, and ATG |
|---|---|
| Sponsor | University of Chicago |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Mucositis
- Nausea
- Elevated transminitis
- Infections
- Skin GvHD
- ATG induced fevers
- Fluid overload
- Neutropenic fevers
- Diarrhea
- Hypertension
- Upper GI GvHD
- Renal insufficiency
Key clinical trials
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations (PHASE2)
- Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial (PHASE4)
- Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (PHASE2)
- Allo HSCT for High Risk Hemoglobinopathies (PHASE2)
- Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML (PHASE1, PHASE2)
- Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT (PHASE2)
- Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation (PHASE2)
- Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fludarabine, Busulfan, and ATG CI brief — competitive landscape report
- Fludarabine, Busulfan, and ATG updates RSS · CI watch RSS
- University of Chicago portfolio CI
Frequently asked questions about Fludarabine, Busulfan, and ATG
What is Fludarabine, Busulfan, and ATG?
Fludarabine, Busulfan, and ATG is a Small molecule drug developed by University of Chicago.
Who makes Fludarabine, Busulfan, and ATG?
Fludarabine, Busulfan, and ATG is developed by University of Chicago (see full University of Chicago pipeline at /company/university-of-chicago).
What development phase is Fludarabine, Busulfan, and ATG in?
Fludarabine, Busulfan, and ATG is in Phase 1.
What are the side effects of Fludarabine, Busulfan, and ATG?
Common side effects of Fludarabine, Busulfan, and ATG include Mucositis, Nausea, Elevated transminitis, Infections, Skin GvHD, ATG induced fevers.